Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 9/20 | 0.33 |
| ▸ | HTR2B | P41595 | 8/20 | 0.33 |
| ▸ | HTR2A | P28223 | 6/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519016 | 0.90 | GBA1 (0.34) | — | |
| Bromide SCHEMBL28426746 | 0.88 | GBA1 (0.33) | — | |
| SCHEMBL10037070 | 0.82 | EPHX2 (0.37) | MAOBKDM1A | |
| SCHEMBL15593375 | 0.81 | ACHE (0.38) | — | |
| SCHEMBL14416818 | 0.81 | GAA (0.34) | LMNA | |
| SCHEMBL13331319 | 0.81 | GBA1 (0.30) | — | |
| SCHEMBL24310936 | 0.80 | EPHX2 (0.40) | MAOBKDM1A | |
| SCHEMBL22893113 | 0.80 | EPHX2 (0.40) | MAOBKDM1A | |
| SCHEMBL22906294 | 0.80 | EPHX2 (0.40) | MAOBKDM1A | |
| SCHEMBL22893117 | 0.80 | EPHX2 (0.40) | MAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352382-B2 | Mito-lonidamine, compositions and methods of use | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11274114-B2 | Modified mito-metformin compounds and methods of synthesis and use thereof | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210061830-A1 | MITO-LONIDAMINE, COMPOSITIONS AND METHODS OF USE | AIX-MARSEILLE UNIVERSITE (FR) | 2021-03-04 | — | — | US | disclosed |
| US-10576093-B2 | Neuroprotection by mitochondria-targeted metformin | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190091245-A1 | Neuroprotection by mitochondria-targeted metformin | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-28 | — | — | US | disclosed |
| US-9956233-B2 | Neuroprotection by mitochondria-targeted metformin | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170275313-A1 | MODIFIED MITO-METFORMIN COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | THE MEDICAL COLLEGE OF WISCONSIN, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170106006-A1 | Neuroprotection by Mitochondria-Targeted Metformin | AIX-MARSEILLE UNIVERSITE (FR) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274114-B2 | Modified mito-metformin compounds and methods of synthesis and use thereof | TFAM, MFN2, MT-ND5 | MAOB 1059/4885KDM1A 1930/4885CXCR4 4315/4885 |
| US-20170275313-A1 | MODIFIED MITO-METFORMIN COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | TFAM, MFN2, MT-ND5 | MAOB 1059/4885KDM1A 1930/4885CXCR4 4315/4885 |
| US-20210061830-A1 | MITO-LONIDAMINE, COMPOSITIONS AND METHODS OF USE | COX5B, COX5A, LONP1 | MAOB 403/4885KDM1A 2121/4885CXCR4 1533/4885 |
| US-20170106006-A1 | Neuroprotection by Mitochondria-Targeted Metformin | NLN, MFN2, TFAM | MAOB 845/4885KDM1A 3249/4885CXCR4 3947/4885 |
| US-10576093-B2 | Neuroprotection by mitochondria-targeted metformin | NLN, MFN2, TFAM | MAOB 845/4885KDM1A 3249/4885CXCR4 3947/4885 |
| US-11352382-B2 | Mito-lonidamine, compositions and methods of use | COX5B, COX5A, LONP1 | MAOB 403/4885KDM1A 2121/4885CXCR4 1533/4885 |
| US-20190091245-A1 | Neuroprotection by mitochondria-targeted metformin | NLN, MFN2, TFAM | MAOB 845/4885KDM1A 3249/4885CXCR4 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.